Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action

Neutral and cationic organometallic ruthenium(II) piano stool complexes of the type [(η⁶-cymene)RuCl(X)(Y)] (complexes R1-R8) has been synthesized and characterized. In cationic complexes, X, Y is either a η² phosphorus ligand such as 1,1-bis(diphenylphosphino)methane (DPPM) and 1,2-bis(diphenylphosphino)ethane (DPPE) or partially oxidized ligands such as 1,2-bis(diphenylphosphino)methane monooxide (DPPMO) and 1,2-bis(diphenylphosphino)ethane monooxide (DPPEO) which are strong hydrogen bond acceptors. In neutral complexes, X is chloride and Y is a monodentate phosphorous donor. Complexes with DPPM and DPPMO ligands ([(η⁶-cymene)Ru(η²-DPPM)Cl]PF₆ (R2), [(η⁶-cymene)Ru(η²-DPPMO)Cl]PF₆ (R3), [(η⁶-cymene)Ru(η¹-DPPM)Cl₂] (R5) and [(η⁶-cymene)Ru(η¹-DPPMO)Cl₂] (R6) show good cytotoxicity. Growth inhibition study of several human cancer cell lines by these complexes has been carried out. Mechanistic studies for R5 and R6 show that inhibition of cancer cell growth involves both cell cycle arrest and apoptosis induction. Using an apoptosis PCR array, we identified the sets of anti-apoptotic genes that were down regulated and pro-apoptotic genes that were up regulated. These complexes were also found to be potent metastasis inhibitors as they prevented cell invasion through matrigel. The complexes were shown to bind DNA in a non intercalative fashion and cause unwinding of plasmid DNA in cell-free medium by competitive ethidium bromide binding, viscosity measurements, thermal denaturation and gel mobility shift assays.     

Synthesis, structure, and characterization of some ruthenium arene complexes of N-(arylmethylene)-2-(methylthio)anilines and 2-(methylthio)aniline

A series of cationic, half-sandwich ruthenium complexes with the general formula [(η⁶-p-cymene)RuCl(MeSC₆H₄2-NCHAr)][PF₆] (3a-h), have been prepared from the reaction of [(η⁶-p-cymene)RuCl₂]₂ with various N,S-donor Schiff base ligands derived from 2-(methylthio)aniline and several substituted benzaldehydes. The related aniline complex [(η⁶-p-cymene)RuCl(MeS-C₆H₄-2-NH₂)][PF₆] (4) was synthesized from 2-(methylthio)aniline. All of the ruthenium complexes were characterized by IR, ¹H NMR, and UV/Vis spectroscopies. The molecular structure of complex 4 was determined by X-ray crystallography.     

Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells

The complexes [Ru(η⁶-p-cymene)(CQ)Cl₂] (1), [Ru(η⁶-benzene)(CQ)Cl₂] (2), [Ru(η⁶-p-cymene)(CQ)(H₂O)₂][BF₄]₂ (3), [Ru(η⁶-p-cymene)(en)(CQ)][PF₆]₂ (4), [Ru(η⁶-p-cymene)(η⁶-CQDP)][BF₄]₂ (5) (CQ = chloroquine base; CQDP = chloroquine diphosphate; en = ethylenediamine) interact with DNA to a comparable extent to that of CQ and in analogous intercalative manner with no evidence for any direct contribution of the metal, as shown by spectrophotometric and fluorimetric titrations, thermal denaturation measurements, circular dichroism spectroscopy and electrophoresis mobility shift assays. Complexes 1-5 induced cytotoxicity in Jurkat and SUP-T1 cancer cells primarily via apoptosis. Despite the similarities in the DNA binding behavior of complexes 1-5 with those of CQ the antitumor properties of the metal drugs do not correlate with those of CQ, indicating that DNA is not the principal target in the mechanism of cytotoxicity of these compounds. Importantly, the Ru-CQ complexes are generally less toxic toward normal mouse splenocytes and human foreskin fibroblast cells than the standard antimalarial drug CQDP and therefore this type of compound shows promise for drug development.     

Syntheses, spectroscopic properties and crystal structures of two organoruthenium (II) complexes of bipyridines: [{Cp*Ru(2,2′-bipy)}2(μ-Cl)][PF6] and [{(η-p-cymene)Ru}2(μ-OH)2(4,4′-bipy)]2[BF4]4

Interaction of [Cp*RuCl(μ-Cl)]₂ with 2,2′-bipyridine (2,2′-bipy) in the presence of Na[PF₆] gave a chloride bridging dinuclear complex [{Cp*Ru(2,2′-bipy)}₂(μ-Cl)][PF₆] (1). In the crystal structure, the cation [{Cp*Ru(2,2′-bipy)}₂(μ-Cl)]⁺ contains a bent Ru-Cl-Ru linkage with an angle of 141.87(12)°. The tris(μ-hydroxo)diruthenium complex [{(η⁶-p-cymene)Ru}₂(μ-OH)₃][BF₄] in acetone solution was treated by 4,4′-bipyridine (4,4′-bipy) to give a hydroxo-bridged tetranuclear complex [{(η⁶-p-cymene)Ru}₂(μ-OH)₂(μ-4,4′-bipy)]₂[BF₄]₄ (2). Complex 2 consists of four (η⁶-p-cymene)Ru moieties connected by two 4,4′-bipy and four hydroxo-bridging groups, forming a novel metallomacrocycle with alternating hydroxyl and 4,4′-bipy bridges between the ruthenium atoms. Spectroscopic properties along with electrochemistry of two organoruthenium (II) complexes 1 and 2 are reported.     

Interactions of arene-Ru(II)-chloroquine complexes of known antimalarial and antitumor activity with human serum albumin (HSA) and transferrin

The interactions of π-arene-Ru(II)-chloroquine complexes with human serum albumin (HSA), apotransferrin and holotransferrin have been studied by circular dichroism (CD) and UV-Visible spectroscopies, together with isothermal titration calorimetry (ITC). The data for [Ru(η⁶-p-cymene)(CQ)(H₂O)Cl]PF₆ (1), [Ru(η⁶-benzene)(CQ)(H₂O)Cl]PF₆ (2), [Ru(η⁶-p-cymene)(CQ)(H₂O)₂][PF₆]₂ (3), [Ru(η⁶-p-cymene)(CQ)(en)][PF₆]₂ (4), [Ru(η⁶-p-cymene)(η⁶-CQDP)][BF₄]₂ (5) (CQ: chloroquine; DP: diphosphate; en: ethylenediamine), in comparison with CQDP and [Ru(η⁶-p-cymene)(en)Cl][PF₆] (6) as controls demonstrate that 1, 2, 3, and 5, which contain exchangeable ligands, bind to HSA and to apotransferrin in a covalent manner. The interaction did not affect the α-helical content in apotransferrin but resulted in a loss of this type of structure in HSA. The binding was reversed in both cases by a decrease in pH and in the case of the Ru-HSA adducts, also by addition of chelating agents. A weaker interaction between complexes 4 and 6 and HSA was measured by ITC but was not detectable spectroscopically. No interactions were observed for complexes 4 and 6 with apotransferrin or for CQDP with either protein. The combined results suggest that the arene-Ru(II)-chloroquine complexes, known to be active against resistant malaria and several lines of cancer cells, also display a good transport behavior that makes them good candidates for drug development.     

Activity of homobimetallic ruthenium alkylidene complexes on intermolecular [2+2+2] cyclotrimerisation reactions of terminal alkynes

The activity of homobimetallic ruthenium alkylidene complexes, [(p-cymene)Ru(Cl)(μ-Cl)₂Ru(Cl)(CHPh)(PCy₃)] [Ru-I] and [(p-cymene)Ru(Cl)(μ-Cl)₂Ru(Cl)(CHPh)(IPr)] [Ru-II], on intermolecular [2+2+2] cyclotrimerisation reactions of monoynes has been investigated for the first time. It was found that these complexes can catalyse the chemo and regioselective cyclotrimerisation reactions of alkynes at both 25 and 50 °C in polar, aprotic solvents. The catalytic activity of [Ru-I] and [Ru-II] was compared to other well-known ruthenium catalysts such as Grubbs first generation catalyst [RuCl₂(CHPh)(PCy₃)₂] [Ru-III], [RuCl(μ-Cl)(p-cymene)]₂ [Ru-IV] and [RuCl₂(p-cymene)PCy₃] [Ru-V] complexes. To examine the effect of the steric hinderance of substrates on the regioselectivity of the reaction, a series of sterically hindered silicon containing alkynes (1a, 1b, 1c) were used. It was shown that the isomeric product distribution of the reaction shifts from 1,2,4-trisubstituted arenes to 1,3,5-trisubstituted arenes as the steric hinderance on the substrates increases. These homobimetallic ruthenium alkylidene complexes also catalysed regio- and chemo-selective cross-cyclotrimerisation reactions between silicon-containing alkynes (1a, 1b, 1c) and aliphatic alkynes (1d-g).     

Short-bite aminobis(phosphonite) containing olefinic functionalities, PhN{P(OC6H3(OMe-o)(C3H5-p))2}2: Synthesis and transition metal complexes

Short-bite aminobis(phosphonite) containing olefinic functionalities, PhN{P(OC₆H₃(OMe-o)(C₃H₅-p))₂}₂ (1) was synthesized by reacting PhN(PCl₂)₂ with eugenol in the presence of triethylamine. The ligand 1 acts as a bidentate chelating ligand toward metal complexes [M(CO)₄(C₅H₁₀NH)₂] forming [M(CO)₄{η²-PhN{P(OC₆H₃(OMe-o)(C₃H₅-p))₂}₂}] (M = Mo, 2; W, 3). The reaction between 1 and [CpFe(CO)₂]₂ leads to the cleavage of one of the P-N bonds due to the metal assisted hydrolysis to give a mononuclear complex [CpFe(CO){P(O)(OC₆H₃(OMe-o)(C₃H₅-p))₂}{PhN(H)(P(OC₆H₃(OMe-o)(C₃H₅-p))₂)}] (4). Treatment of 1 with gold(I) derivative, [AuCl(SMe₂)] resulted in the formation of a dinuclear complex, [(AuCl)₂{PhN{P(OC₆H₃(OMe-o)(C₃H₅-p))₂}₂}] (5) with a Au···Au distance of 3.118(2) Å indicating the possibility of aurophilic interactions. An equimolar reaction between 1 and [Ru(η⁶-p-cymene)Cl₂]₂ afforded a tri-chloro-bridged bimetallic complex [(η⁶-p-cymene)Ru(μ-Cl)₃Ru{PhN(P(OC₆H₃(OMe-o)(C₃H₅-p))₂)₂}Cl] (6). The crystal structures of 1-3 and 5 were established by single crystal X-ray diffraction studies.     

In vitro leishmanicidal activity and theoretical insights into biological action of ruthenium(II) organometallic complexes containing anti-inflammatories

Leishmaniasis, a neglected tropical disease caused by protozoans of the genus Leishmania, kills around 20–30 thousand people in Africa, Asia, and Latin America annually and, despite its potential lethality, it can be treated and eventually cured. However, the current treatments are limited owing to severe side effects and resistance development by some Leishmania. These factors make it urgent to develop new leishmanicidal drugs. In the present study, three ruthenium(II) organometallic complexes containing as ligands the commercially available anti-inflammatories diclofenac (dic), ibuprofen (ibu), and naproxen (nap) were synthesized, characterized, and subjected to in vitro leishmanicidal activity. The in vitro cytotoxicity assays against Leishmania (L.) amazonensis and Leishmania (L.) infantum promastigotes have shown that complexes [RuCl(dic)(η⁶-p-cymene)] (1) and [RuCl(nap)(η⁶-p-cymene)] (3) were active against both Leishmania species. Complex [RuCl(ibu)(η⁶-p-cymene)] (2) has exhibited no activity. The IC₅₀ values for the two active complexes were respectively 7.42 and 23.55 μM, for L. (L.) amazonensis, and 8.57 and 42.25 μM, for L. (L.) infantum. Based on the toxicological results and computational analysis, we proposed a correlation between the complexes and their activity. Our results suggest both complexation to ruthenium(II) and ligands structure are key elements to leishmanicidal activity.     

Synthesis and characterization of Ru(arene) complexes of bispyrazolylazines: Catalytic hydrogen transfer of ketones

The bis(pyrazol-1-yl)azine ligands 2,3-bis(pyrazol-1-yl)quinoxaline (bpzqnx), 2,3-bis(pyrazol-1-yl)pyrazine (bpzprz) and 3,6-bis(3,5-dimethylpyrazol-1-yl)pyridazine (bpz*pdz) were prepared by the reaction of pyrazolate salts and the corresponding azine dichloride derivatives. The reaction of these ligands with Ru(arene) precursors led to the mononuclear complexes [RuCl(arene)(L)]BPh₄ (arene = p-cymene, L = bpzqnx, 1, bpzprz, 5, bpz*pdz, 7; arene = C₆H₆, L = bpzqnx, 2, bpzprz, 6, bpz*pdz, 8) with the N-donor ligand coordinated in a bidentate chelate way. In general, the ligands coordinate through one pyrazole ring and the azine, except in the cases of 1 and 2 where the two pyrazolyl rings are coordinated to the metal in a symmetrical way. When the reactions between the ruthenium precursors and bpzqnx are carried out in MeOH, the complexes [RuCl(arene)(OMepzqnx)]BPh₄ with partially methanolyzed ligands are isolated (arene = p-cymene, 3; C₆H₆, 4). In this process a methoxy group has replaced one of the pyrazole groups in the ligand. The X-ray structures of 6 and 7 have been determined. These compounds have a three-legged piano-stool structure with cations and anions packed through weak interactions. Complexes 1-8 are active in ketone hydrogenation transfer processes even in the absence of base.     

Metal–drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells

In our ongoing search for new metal-based chemotherapeutic agents against leishmaniasis and Chagas disease, six new ruthenium–ketoconazole (KTZ) complexes have been synthesized and characterized, including two octahedral coordination complexes—cis,fac-[Ru^IICl₂(DMSO)₃(KTZ)] (1) and cis-[Ru^IICl₂(bipy)(DMSO)(KTZ)] (2) (where DMSO is dimethyl sulfoxide and bipy is 2,2′-bipyridine)—and four organometallic compounds—[Ru^II(η⁶-p-cymene)Cl₂(KTZ)] (3), [Ru^II(η⁶-p-cymene)(en)(KTZ)][BF₄]₂ (4), [Ru^II(η⁶-p-cymene)(bipy)(KTZ)][BF₄]₂ (5), and [Ru^II(η⁶-p-cymene)(acac)(KTZ)][BF₄] (6) (where en is ethylenediamine and acac is acetylacetonate); the crystal structure of 3 is described. The central hypothesis of our work is that combining a bioactive compound such as KTZ and a metal in a single molecule results in a synergy that can translate into improved activity and/or selectivity against parasites. In agreement with this hypothesis, complexation of KTZ with Ru^II in compounds 3–5 produces a marked enhancement of the activity toward promastigotes and intracellular amastigotes of Leishmania major, when compared with uncomplexed KTZ, or with similar ruthenium compounds not containing KTZ. Importantly, the selective toxicity of compounds 3–5 toward the leishmania parasites, in relation to human fibroblasts and osteoblasts or murine macrophages, is also superior to the selective toxicities of the individual constituents of the drug. When tested against Trypanosoma cruzi epimastigotes, some of the organometallic complexes displayed activity and selectivity comparable to those of free KTZ. A dual-target mechanism is suggested to account for the antiparasitic properties of these complexes.     

Synthesis, characterization and antimalarial activity of new chromium arene-quinoline half sandwich complexes

Organometallic analogs of chloroquine (CQ) are of interest as drug candidates that may be able to overcome the widespread chloroquine resistance developed by malaria parasites. Two new chromium arene CQ-analogs: [η⁶-N-(7-chloroquinolin-4-yl)-N′-(2-dimethylamino-methylbenzyl)-ethane-1,2-diamine]tricarbonylchromium 4 and [η⁶-N-(7-chloroquinolin-4-yl)-N′-(2-dimethylaminobenzyl)-ethane-1,2-diamine]tricarbonylchromium 9 have been synthesized and characterized. In addition, X-ray crystal structures of the intermediates (η⁶-benzyldimethylamine)tricarbonylchromium 2, [η⁶-2-((dimethylamino)methyl) benzaldehyde]tricarbonylchromium 3 and p-(η⁶-dimethylaminobenzaldehyde)tricarbonyl chromium 8 are reported. Compound 4 was more active than chloroquine against both CQ-sensitive and CQ-resistant strains of Plasmodium falciparum when antimalarial activity was tested in vitro. The activity of 4 against the CQ-resistant parasite strain was twice as high as for the organic ligand alone (IC₅₀ values of 33.9 nM versus 63.1 nM).     

Synthesis and complexation of tetrakis(diphenylphosphinomethyl)calix[4]arene adopting the 1,3-alternate conformation

Novel upper-rim modified tetraphosphinocalix[4]arenes (5a-b) adopting 1,3-alternate conformation have been synthesized. Reaction of 5,11,17,23-tetrachloromethyl-25,26,27,28-tetrahydroxycalix[4]arene (1) with Ph₂POEt gave 5,11,17,23-tetrakis(diphenylphosphinoylmethyl)-25,26,27,28-tetrahydroxycalix[4]arene (2). Tetra-O-substitution of 2 with n-propyl iodide or benzyl bromide in the presence of K₂CO₃ carried out to afford 5,11,17,23-tetrakis(diphenylphosphinoylmethyl)-25,26,27,28-tetrapropoxy-(3a) or -benzyloxycalix[4]arene (3b), whereas di-O-substituted calix[4]arene, 5,11,17,23-tetrakis(diphenylphosphinoylmethyl)-25,27-dipropoxy-26,28-dihydroxycalix[4]arene (4), was obtained exclusively when Na₂CO₃ was used as base. Reduction of 3a-b with PhSiHCl₂ afforded 5,11,17,23-tetrakis(diphosphinomethyl)-25,26,27,28-tetrapropoxy-(5a) and -tetrabenzyloxycalix[4]arene (5b). ¹H and ¹³C NMR analysis reveals that the phosphines (5a-b) and the tetra-O-substituted phosphine oxides (3a-b) adopt 1,3-alternate conformation, while the parent tetrahydroxy-(2) and the di-O-propylated phosphine oxide (4) adopt cone-conformation. The X-ray structure indicates that the calix[4]arene moieties in 4 a pinched-cone conformation in solid state. Complexation of the phosphine ligand (5a) with [RuCl₂(p-cymene)]₂ affords the tetranuclear complexes, [{RuCl₂(p-cymene)}₂ · 5a] (6), as 1,3-alternate conformer.     

The unexpected reactions of [RuCl3(2mqn)NO] (H2mqn=2-methyl-8-quinolinol) with 2-chloro-8-quinolinol (H2cqn) and of [RuCl(2cqn)(2mqn)NO] on photoirradiation

The reaction of [RuCl₃(2mqn)NO]⁻ (H2mqn=2-methyl-8-quinolinol) with 2-chloro-8-quinolinol (H2cqn) afforded cis-1 [RuCl(2cqn)(2mqn)NO] (the oxygen of 2cqn is trans to the NO) (complex 1), cis-1 [RuCl(2cqn)(2mqn)NO] (the oxygen of 2mqn is trans to the NO) (complex 2) and a 1:1 mixture of cis-2 [RuCl(2cqn)(2mqn)NO] (the oxygen of 2mqn is trans to the NO) and cis-2 [RuCl(2cqn)(2mqn)NO] (the oxygen of 2cqn is trans to the NO) (complex 3). The reaction was compared with that of [RuCl₃(2mqn)NO]⁻ with 8-quinolinol (Hqn) or 5-chloro-8-quinolinol (H5cqn). Photoirradiation reaction of complex 1 at room temperature in deaerated CH₂Cl₂ in the presence of NO gave trans-[RuCl(2cqn)(2mqn)NO] (the Cl is trans to the NO) and complex 2 with recovery of complex 1. The reaction was contrasted with that of cis-1 [RuCl(qn)(2mqn)NO] or cis-1 [RuCl(5cqn)(2mqn)NO]. The crystal structure of complex 1 was determined by X-ray diffraction. The reactions were examined under consideration of atomic charge of the phenolato oxygen in 8-quinolinol and its derivatives calculated at the restricted Hartree-Fock/6-311G** level.     

Synthesis, characterisation and natural abundance Os NMR spectroscopy of hydride bridged triosmium clusters with chiral diphosphine ligands

Treatment of [Os₃(μ-H)₂(CO)₁₀] with the chiral diphosphines BINAP, tolBINAP [(R)-2,2′-bis(di-4-tolylphosphino)-1,1′-binaphthyl], DIOP [(4R,5R)-(−)-O-isopropenylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane] affords [Os₃(μ-H)₂(CO)₈(μ-L)] (L = BINAP (1), tolBINAP (2), DIOP (4)) in high yield. The X-ray structures for 1, 2 and 4 are reported, and structural and spectroscopic comparisons are made between these clusters and [Os₃(μ-H)₂(CO)₈(μ-L)] (L = dppm (5), dppe (6), dppp (7)) which were synthesised similarly. Compounds 5 to 7 were previously synthesised by hydrogenation of 1,2-[Os₃(CO)₁₀(μ-L)] but the route from [Os₃(μ-H)₂(CO)₁₀] is preferable. The H-bridged Os?Os distances are similar in 1, 2 and 4 indicating that these species are formally unsaturated 46-electron clusters. The P?P distances vary from 4.24 to 4.30 Å in 1 and 2, respectively, to 4.53 Å in 4 and there are related changes in the angles associated with the ligand set around the H-bridged osmium atoms. Introduction of the diphosphine ligands completely suppresses the ability to add CO, to insert acetylene to form a μ-η¹,η²-vinyl compound, and to exchange hydride ligands with styrene-d₈, which are reactions characteristic of [Os₃(μ-H)₂(CO)₁₀]. Clusters 2 and 5-7 were also used to examine the potential of natural abundance ¹⁸⁷Os NMR spectroscopy through techniques based on inverse detection by HMQC, HSQC and HMBC spectroscopy.     

Improving the enantioselectivity of artificial transfer hydrogenases based on the biotin-streptavidin technology by combinations of point mutations

Artificial metalloenzymes based on the incorporation of biotinylated ruthenium piano-stool complexes within streptavidin can be readily optimized by chemical or genetic means. We performed genetic modifications of such artificial metalloenzymes for the transfer hydrogenation of aromatic ketones, by combining targeted point mutations of the host protein. Upon using the P64G-L124V double mutant of streptavidin in combination with the [η⁶-(p-cymene)Ru(Biot-p-L)Cl] complex, the enantioselectivity can be increased up to 98% ee (R) for the reduction of p-methylacetophenone, which is the highest selectivity obtained up to date with an artificial transfer hydrogenase.     

Synthesis and structural characterizations of para-bis(dialkyl/diarylphosphino)phenylenes built around tetrahalogenated benzene cores

Double deprotonation of 1,2-dibromo-4,5-difluorobenzene and 1-bromo-2-chloro-4,5-difluorobenzene by lithium diisopropylamide (LDA) in ethereal solutions is facile at very low temperatures (T < −90 °C). The organo-dilithium intermediates thus generated react readily with chlorophosphines ClPR₂ (R = Ph and/or ⁱPr), producing 1,2-dibromo-3,6-bis(diphenylphosphino)-4,5-difluorobenzene (1a), 1,2-dibromo-3,6-bis(diisopropylphosphino)-4,5-difluorobenzene (1b) and 1-bromo-2-chloro-3,6-bis(diphenylphosphino)-4,5-difluorobenzene (1c). Corresponding P-oxides 2a-c are obtained by oxidation of 1a-c with H₂O₂. Analogous reactions of 1,2-dibromo-4,5-difluorobenzene and 1-bromo-2-chloro-4,5-difluorobenzene with only 1 equiv. of LDA do not result in selective monodeprotonations, as 1a and 1c are formed preferentially after ClPPh₂ quench. All of the isolated new compounds were fully characterized by multinuclear NMR spectroscopy, elemental analysis and/or mass-spectrometry. In addition, 1a, 1c, 2a, and 2b were characterized by single crystal X-ray diffraction methods.     

Iridoids from Gentiana loureirii

Iridoid glycosides, 2′,3′,6′-tri-O-acetyl-4′-O-trans-p-(O-β-d-glucopyranosyl)coumaroyl-7-ketologanin (1), 2′-O-caffeoylloganic acid (2), 2′-O-p-hydroxybenzoylloganic acid (3), 2′-O-trans-p-coumaroylloganic acid (4), and 2′-O-cis-p-coumaroylloganic acid (5), were isolated from whole plants of Gentiana loureirii along with six known iridoids, 7-ketologanin (6), loganin (7), loganic acid (8), sweroside, boonein, and isoboonein, and three other known compounds. Their structures were elucidated by spectroscopic means and chemical correlations. The isolated iridoids were evaluated for antibacterial and antioxidant activities, but were either inactive or very weakly active.     

Synthesis, structure, and catalytic activity of chiral Cu(II) and Ag(I) complexes with (S,S)-1,2-diaminocyclohexane-based N4-donor ligands

Condensation of (S,S)-1,2-cyclohexanediamine with 2 equiv. of 2-pyridine carboxaldehyde in toluene in the presence of molecular sieves at 70 °C gives N,N′-bis(pyridin-2-ylmethylene)-(S,S)-1,2-cyclohexanediamine (S,S-1) in 95% yield. Reduction of 1 with an excess of NaBH₄ in MeOH at 50 °C gives N,N′-bis(pyridin-2-ylmethyl)-(S,S)-1,2-cyclohexanediamine (S,S-2) in 90% yield. Reaction of 1 or 2 with 1 equiv. of CuCl₂ · 2H₂O in methanol gives complexes [N-(pyridin-2-ylmethylene)-(S,S)-1,2-cyclohexanediamine]CuCl₂ (3) and [Cu(S,S-2)(H₂O)]Cl₂ · H₂O (4), respectively, in good yields. Complex 4 can further react with 1 equiv. of CuCl₂ · 2H₂O in methanol to give [Cu(S,S-2)][CuCl₄] (5) in 75% yield. The rigidity of the ligand coupled with the steric effect of the free anion plays an important role in the formation of the helicates. Treatment of ligand S,S-1 with AgNO₃ induces a polymer helicate {[Ag(S,S-1)][NO₃]}_n (6), while reaction of ligand 2 with AgPF₆ or AgNO₃ in methanol affords a mononuclear single helicate [Ag(S,S-2)][PF₆] (7) or a dinuclear double helicate [Ag₂(S,S-2)₂][NO₃]₂ · 2CH₃OH (8) in good yields, respectively. All compounds have been characterized by various spectroscopic data and elemental analyses. Compounds 1, 3-5, 7 and 8 have been further subjected to single-crystal X-ray diffraction analyses. The Cu(II) complexes do not show catalytic activity for allylation reaction, in contrast to Ag(I) complexes, but they do show catalytic activity for Henry reaction (nitroaldol reaction) that Ag(I) complexes do not.     

Synthesis and characterization of platinum(IV) complexes with N,S and S,S heterocyclic ligands

The reactions of [PtMe₃(OAc)(bpy)] (4) with the N,S and S,S containing heterocycles, pyrimidine-2-thione (pymtH), pyridine-2-thione (pytH), thiazoline-2-thione (tztH) and thiophene-2-thiol (tptH), resulted in the formation of the monomeric complexes [PtMe₃(-κS)(bpy)] ( = pymt, 5; pyt, 6; tzt, 7; tpt, 8), where the heterocyclic ligand is coordinated via the exocyclic sulfur atom. In contrast, in the reactions of [PtMe₃(OAc)(Me₂CO)_x] (3, x = 1 or 2) with pymtH, pytH, tztH and tptH dimeric complexes [{PtMe₃(μ-)}₂] (μ- = pymt, 9; pyt, 10; tzt, 11) and the tetrameric complex [{PtMe₃(μ₃-tpt-κS)}₄] (12), respectively, were formed. The complexes were characterized by microanalyses, ¹H and ¹³C NMR spectroscopy and negative ESI-MS (12) measurements. Single-crystal X-ray diffraction analysis of [PtMe₃(pymt-κS)(bpy)] (5) exhibited a conformation where the pymt ligand lies nearly perpendicular to the complex plane above the bpy ligand that was also confirmed by quantum chemical calculations on the DFT level of theory.     

Stepwise syntheses, structure and spectroscopic studies of ruthenium complexes of 2,6-bis(benzimidazol-2-yl)pyridine with o-iminoquinone ancillary ligand

The ruthenium complexes [Ru^II(bbp)(L)(Cl)] (1), [Ru^II(bbp)(L)(H₂O)] (2) and [Ru^II(bbp)(L)(DMSO)] (3) {bbp = 2,6-bis(benzimidazol-2-yl)pyridine, L = o-iminoquinone} have been synthesized in a stepwise manner starting from [Ru^III(bbp)Cl₃]. The single crystal X-ray structures, except for the complex 2, have been determined. All the complexes were characterized by UV-Vis, FT-IR, ¹H NMR, Mass spectroscopic techniques and cyclic voltammetry. The Ru^III/Ru^II couple for complexes 1, 2, and 3 appears at 0.63, 0.49, 0.55 V, respectively versus SCE. It is observed that complex 2, on refluxing in acetonitrile, results into [Ru^II(bbp)(L)(CH₃CN)], 4 which has been prepared earlier in a different method. The structural, spectral and electrochemical properties of complexes 1, 2 and 3 were compared to those of earlier reported complex 4, [Ru^II(bbp)(L)(CH₃CN)].